Source: Eur Respir J 2001; 17: 36-38
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Ledson M., Gallagher M., Hart C.A., Walshaw M.. Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients. Eur Respir J 2001; 17: 36-38

Member's Comments

No comment yet.

Related content which might interest you: Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients Source: Eur Respir J 2004; 23: 851-856 Year: 2004 Burkholderia cepacia complex infection in Czech patients with cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003 Treatment of Burholderia cepacia infection in patients with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 539s Year: 2001 Taurolidine in the management of lung transplant recipients with cystic fibrosis colonized with burkholderia cepacia Source: Eur Respir J 2002; 20: Suppl. 38, 564s Year: 2002 Burkholderia cepacia infection in adult cystic fibrosis patients: Its impact on lung function and survival Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010 Cystic fibrosis: the problem with B. cepacia and more Source: Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria? Year: 2004 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Changes in local and systemic inflammatory markers in cystic fibrosis patients chronically infected with Burkholderia cepacia complex Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 TNF and LTA gene polymorphisms in cystic fibrosis patients with Burkholderia cepacia complex (Bcc) Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis Year: 2021 Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis Source: Eur Respir J 2005; 26: 651-656 Year: 2005 Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002 Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2007; 30: 286-292 Year: 2007 Cyanide in bronchoalveolar lavage is not diagnostic for Pseudomonas aeruginosa in children with cystic fibrosis Source: Eur Respir J 2011; 37: 553-558 Year: 2011 Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007 Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Source: Eur Respir J 2008; 31: 822-829 Year: 2008 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis Source: Eur Respir J 2004; 24 : 631-637 Year: 2004 Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Source: Eur Respir J 2005; 25: 474-481 Year: 2005